Lisa Osborne interviews WCG executive Peter DiBiaso about his experiences as a drug development professional participating in clinical trials investigating new therapies for Parkinson’s disease.
In today's evolving landscape of clinical trials, the competition for trial sites with the right patients and strong retention capabilities is intensifying. Trial sponsors are striving to position themselves as the sponsors of choice by fostering collaborative relationships. This is particularly crucial in conducting research in oncology trials, rare diseases, and other high-demand therapeutic areas.
Imagine a world where a rare disease diagnosis no longer spells a journey of uncertainty and pain. Instead, it begins a collaborative journey where patients, healthcare professionals, and researchers unite to uncover personalized solutions. In this world, trial design isn’t constrained by rigid parameters; it flourishes in the realm of possibility, embracing the nuances of each patient’s experience.
In the ever-evolving landscape of clinical research, technological advancements are reshaping the way studies are conducted, data are analyzed, and breakthroughs are achieved. Among the most transformative innovations in recent years, artificial intelligence (AI) stands out as a game-changer.
When writing SOPs, it’s important to strike the right balance between providing enough detail and avoiding excessive complexity. Insufficient detail increases the likelihood of users improvising on the spot or following widely used, but perhaps inadequate, methods. On the other hand, excessive information can lead to confusion, errors, and mistakes.